Sydney M Crago

In addition to the primary safety and tolerability endpoints, the study also saw signals of biological response from EXN407

MCO-010 demonstrated a statistically significant improvement of best-corrected visual acuity (BCVA) at week 52.

Research estimates that the RVO market with see a compound annual growth rate of 11.9%.

After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.

Advances in virtual reality and AI are helping those with AMD and low vision.

Ferrone’s role will be effective as of March 18, 2024.

The approval marks the first new steroid on the ophthalmic market in more than 15 years.

Anthony Mai, MD, shared results from using the miCOR 700 device, which is a new device from Zeiss, for phacoemulsification cataract surgery at the EnVision Summit 2024. He spoke with Peg Achenbach, OD, FAAO, Executive Director/Global Ambassador Strategies, Ophthalmology and Optometry at MJH Life sciences, on location in Puerto Rico to share more about his presentation.

These 3 participants have received their first aflibercept injection for the treatment of wet AMD.

Glenn Yiu, MD, PhD, was chosen for this grant. Yiu is a retinal specialist and clinician-scientist currently a professor of ophthalmology at the University of California, Davis.

Sydney M Crago, the editor of Modern Retina, talks with Arshad M Khanani, MD, MA, FASRS, about the expanded efficacy data from the GATHER 2 trial for geographic atrophy (GA).

This presentation will outline the safety and bioactivity of KSI-501ABC in patients with diabetic macular edema (DME).

The FDA previously granted Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug designation to ATSN-101 for the treatment of LCA1.

The commercial release of OcuLenz is planned for the first half of 2024. Ocutrx is collaborating with Medicare and insurance providers to ensure the headset's affordability and accessibility.

The kiosk is the first to offer self-service retinal imaging, empowering individuals to capture their own images.

This trial is a multi-center, open-label safety and tolerability study enrolling 30 patients to evaluate a low and high dose of AVD-104 with 3-month follow-up.

Updates include expected timelines for trials for the treatment of wet AMD, DME, GA, and inherited retinal diseases.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

If granted, this device would be assigned an official classification as a Class II device with special controls.

Data will be shared in early 2024 regarding this potential treatment of diabetic retinopathy via eye drop.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

Catch up on a few of our top stories and ones you may have missed in 2023

The suspension is unrelated to product quality and will lift in February of 2024.

Government focus on preventing blindness as well as rising elderly population are key drivers behind this growth.

Boneva is an experienced surgeon skilled in trauma, surgical critical care, emergency surgery, and acute care surgery.

Umedaptanib pegol has potential to improve outcomes if used as a first-line medication prior to patients receiving treatments targeting VEGF.

Sblendorio brings decades of experience in the ophthalmic industry to his position on the Nanoscope board as the company continues to move forward in their commitment to retinal diseases.

The partnership will further the effort to bring VGX-0111, a gene therapy treatment for AMD to patients and providers.

The study saw encouraging results and helped to identify suitable dosing levels for future clinical trials.